Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$313.4M
17M shares
52-week range
$7.18 – $23.63
77% from low
Exchange
NASDAQ
CS
Prenetics Global Ltd is a consumer health and wellness company offering nutrition and longevity products through its flagship brand, IM8. It offers science-backed daily nutrition and longevity products distributed directly to consumers across multiple countries. The company's products are developed with scientific input and are subject to third-party quality certifications.
www.prenetics.comNo one on the platform currently holds PRE.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 31,322 | $605.1K |
| Execution date | Ratio |
|---|---|
| 2023-11-14 | 1-for-15reverse |
No one on the platform has traded PRE yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
New research today on @Prenetics $PRE #sidotiresearch Read note: http://dlvr.it/TTtt5x #investing #smallcap #microcap
View on StockTwits ↗$PRE Reported approximately $92 million in 2025 revenue, a nearly 480% increase from the prior year, driven by acquisitions and expansion into consumer health...
View on StockTwits ↗$PRE earnings pushed out at least a year and losses going up. Worth waiting. Saw this story at Gaia. Hasnt had a good effect on the stock to say the least.
View on StockTwits ↗New research today on @Prenetics $PRE #sidotiresearch Read note: http://dlvr.it/TTYM9G #investing #smallcap #microcap
View on StockTwits ↗$PRE Continues to Exceed Expectations and Receive Preferential Financing https://buff.ly/vAl32E5
View on StockTwits ↗$PRE Prenetics' IM8 Secures $1 Billion Growth Financing from General Catalyst's Customer Value Fund (CVF) Tuesday, 14th July at 1:35 pm IM8 is the fastest-growing premium supplement brand ever recorded — over 50 million servings delivered to date, with approximately 200,000 servings currently delivered daily, and an order every 27 seconds Prenetics raises full-year 2026 IM8 revenue guidance to $210–220 million, up from $190–210 million IM8 expected to reach $300 million in annualized run-rate revenue by year-end 2026 IM8 expected to deliver $400 million or more in full-year 2027 revenue Every $1 invested in customer acquisition has returned $1.44 in gross profit, blended across all mature cohorts
View on StockTwits ↗$PRE CEO Danny Yeung discusses Prenetics' transition from a COVID-era diagnostics business to a wellness brand, and management's view of the category's market opportunity in our latest CEO Chat: https://buff.ly/HV4PDZs
View on StockTwits ↗New research this week on @Prenetics $PRE #sidotiresearch Read note: http://dlvr.it/TT9cH2 #investing #smallcap #microcap
View on StockTwits ↗$PRE Continues to Post Rapid Growth https://buff.ly/VX7WdKG
View on StockTwits ↗https://marketbeat.com/a/8654885/ $PRE Prenetics Global Q1 Earnings Call Highlights
View on StockTwits ↗$PRE Continues Astounding Growth, While Expanding Product Line https://buff.ly/UD4qC7E
View on StockTwits ↗$PRE Q1 '26 Earnings Results & Recap Prenetics raised its full-year 2026 IM8 revenue guidance to $190 million to $210 million, up from the prior range of $180 million to $200 million. Prenetics projects Q2 2026 revenue to be $46 million to $48 million.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $223M | +146.9% | $-3.81 | $-4.72–$-2.88 | — | 2 |
| 2027 | $399M | +79.2% | $-1.84 | $-2.01–$-1.51 | — | 2 |
| 2028 | $565M | +41.7% | $2.13 | $0.28–$3.98 | 9.3× | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| PREPrenetics Global Limited | $19.70 | +5.46% | $335M | — |
| ARMPArmata Pharmaceuticals, Inc. | $4.82 | +11.83% | $177M | — |
| ATLNAtlantic International Corp. | $0.90 | +0.00% | $73M | — |
| CDXSCodexis, Inc. | $1.60 | +0.00% | $172M | — |
| IMDXInsight Molecular Diagnostics Inc. | $3.71 | -17.56% | $120M | — |
| MXCTMaxCyte, Inc. | $1.39 | +9.45% | $149M | — |
| OSUROraSure Technologies, Inc. | $4.02 | +7.20% | $277M | — |
Source: Financial Modeling Prep · peers by sector/industry